



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: Mattheakis et al.

Attorney Docket No.: CYTOP135X1

Application No.: 10/719,988

Examiner: Kailash C. Srivastava

Filed: November 20, 2003


Group: 1657

Title: PREDICTING HEPATOTOXICITY USING
CELL BASED ASSAYS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first-class mail on October 12, 2007 in an envelope addressed to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Signed:


Mary Terry

**INFORMATION DISCLOSURE STATEMENT
BEFORE FINAL ACTION OR NOTICE OF ALLOWANCE
(37 CFR §§ 1.56 AND 1.97(c))**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

10/16/2007 CNEGAI 00000001 10719988

01 FC:1806

180.00 OP

Dear Sir:

The references identified in the attached PTO Form 1449, (copies of non-U.S. references are attached), may be material to examination of the above-identified patent application. Applicants identify these reference(s) in compliance with their duty of disclosure pursuant to 37 CFR §§ 1.56 and 1.97. The Examiner is requested to make the identified reference(s) of official record in this application.


This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this reference indeed constitutes prior art.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits, or after three months from the filing date of this application, whichever event occurred last, but it is believed before the mailing date of either: (i) a final action under §1.113 or (ii) a notice of allowance under §1.311, whichever occurs first.

Accompanying this Information Disclosure Statement is the fee set forth in 37 CFR 1.17(p).

Enclosed is our Check No. ~~13975~~ for \$180.00 in payment of the Information Disclosure Statement Fee. If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CYTOP135X1).

Respectfully submitted,
BEYER WEAVER LLP

A handwritten signature in black ink, appearing to read 'Jeffrey K. Weaver', with a long horizontal flourish extending to the right.

Jeffrey K. Weaver
Registration No. 34,314

P.O. Box 70250
Oakland, CA 94612-0250